Testing two chemotherapy combinations for relapsed pediatric rhabdomyosarcoma
Part of Cancer clinical trials.
This trial compares two treatment combinations—liposomal doxorubicin plus irinotecan versus a different chemotherapy plan—in children and teens whose rhabdomyosarcoma came back or did not respond. It aims to see which option works better and is safer for children who have had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 6 to 18 years old.
- They are strong enough to take treatment (performance score at least 50 on the child/teen or adult-style scale).
- They have at least 12 weeks expected survival, and at least one measurable tumor area on scans.
- Their heart function is okay: good heart pumping on ultrasound, no signs of blocked blood flow on ECG, and no prior dangerous heart rhythm problems needing medicine.
- They have fully recovered from side effects of prior cancer treatment, including certain chemotherapy, radiation, immune treatments, and any stem cell transplant timing rules.
- Key blood and organ tests are in safe ranges (white blood cells, platelets, liver, bilirubin, and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
This trial tests a new combination of chemotherapy drugs (irinotecan, temozolomide, and vincristine) for children whose solid tumors have come back or not responded to standard treatment. It aims to see if a specific gene test can help doctors choose the right dose of irinotecan to reduce side effects.
This study tests different treatment plans for children with rhabdomyosarcoma based on their individual risk factors. It aims to find the best therapy for each child, potentially improving outcomes.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or haven't responded to standard treatment. The goal is to see if this drug mix can shrink or control the tumors.
This trial tests a combination of three chemotherapy drugs (irinotecan, temozolomide, and vincristine) in children and teens whose solid tumors have come back or stopped responding to standard treatment. The goal is to see if this combination can help shrink or control the tumors.
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
Hear when a new Rhabdomyosarcoma, Child trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.